Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: Feasibility and 1-year results of a randomized clinical trial

JAMA Surgery

Volumn 149, Issue 7, 2014, Pages 716-726

  Halperin, Florencia ^a   Ding, Su Ann ^b   Simonson, Donald C ^a   Panosian, Jennifer ^b   Goebel Fabbri, Ann ^b   Wewalka, Marlene ^b   Hamdy, Osama ^b   Abrahamson, Martin ^b   Clancy, Kerri ^a   Foster, Kathleen ^b   Lautz, David ^a   Vernon, Ashley ^a   Goldfine, Allison B ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOMETABOLIC RISK; CONTROLLED STUDY; FAT MASS; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH STATUS; HUMAN; INTERMETHOD COMPARISON; LEAN BODY WEIGHT; LIFESTYLE MODIFICATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; ROUX Y ANASTOMOSIS; SCORING SYSTEM; SELF REPORT; STOMACH BYPASS; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT REDUCTION; YOUNG ADULT;

ADULT; AGED; ANASTOMOSIS, ROUX-EN-Y; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEASIBILITY STUDIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; LIPIDS; MALE; MIDDLE AGED; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84904401688     PISSN: 21686254     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamasurg.2014.514     Document Type: Article

References (41)

1. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in US diabetes care, 1999-2010. N Engl J Med. 2013;368(17):1613-1624.
2. National Institutes of Health. Highest priority challenge topics [page 20]. https://grants.nih.gov/archive/grants/funding/challenge-award/High- Priority-Topics.pdf. Accessed April 23, 2014.
3. Knowler WC, Barrett-Connor E, Fowler SE, et al Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. (Pubitemid 34437694)
4. Wadden TA, West DS, Delahanty L, et al Look AHEAD Research Group. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring). 2006;14(5):737-752. (Pubitemid 46219712)
5. Pi-Sunyer X, Blackburn G, Brancati FL, et al Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care. 2007;30(6):1374-1383. (Pubitemid 46871141)
6. Hamdy O, Carver C. The Why WAIT program: improving clinical outcomes through weight management in type 2 diabetes. Curr Diab Rep. 2008;8(5):413-420.
7. Giusti J, Rizzotto JA. Interpreting the Joslin Diabetes Center and Joslin Clinic clinical nutrition guideline for overweight and obese adults with type 2 diabetes. Curr Diab Rep. 2006;6(5):405-408. (Pubitemid 44823095)
8. National Heart, Lung, and Blood Institute. Guidelines on overweight and obesity: electronic textbook. https://www.nhlbi.nih.gov/guidelines/obesity/e- txtbk/txgd/4142.htm. Accessed April 23, 2014.
9. Beriault K, Carpentier AC, Gagnon C, et al. Reproducibility of the 6-minute walk test in obese adults. Int J Sports Med. 2009;30(10):725-727.
10. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III: tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32(1):40-66.
11. Centers for Disease Control and Prevention. Barriers to Being Physically Active Quiz. National Center for Chronic Disease Prevention and Health Promotion. http://www.cdc.gov/diabetes/ndep/pdfs/8-road-to-health-barriers-quiz- 508.pdf. Accessed May 2, 2014.
12. UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care. 1999;22(7):1125-1136.
13. Welch G, Weinger K, Anderson B, Polonsky WH. Responsiveness of the Problem Areas in Diabetes (PAID) questionnaire. Diabet Med. 2003;20(1):69-72. (Pubitemid 36104203)
14. Polonsky WH, Anderson BJ, Lohrer PA, et al. Assessment of diabetes-related distress. Diabetes Care. 1995;18(6):754-760.
15. Kolotkin RL, Crosby RD. Psychometric evaluation of the Impact of Weight on Quality of Life-Lite questionnaire (IWQOL-Lite) in a community sample. Qual Life Res. 2002;11(2):157-171. (Pubitemid 34438162)
16. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979; 28(12):1039-1057.
17. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567-1576.
18. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309(21):2240-2249.
19. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299(3):316-323. (Pubitemid 351159368)
20. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366(17):1577-1585.
21. Frye RL, August P, Brooks MM, et al; BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503-2515.
22. Maggard-Gibbons M, Maglione M, Livhits M, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: a systematic review. JAMA. 2013;309(21):2250-2261.
23. Wing RR; Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170(17):1566-1575.
24. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753-761. (Pubitemid 47295642)
25. Sjöström L, Narbro K, Sjöström CD, et al Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741-752. (Pubitemid 47295641)
26. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56-65.
27. Vest AR, Heneghan HM, Agarwal S, Schauer PR, Young JB. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart. 2012;98(24):1763-1777.
28. Johnson BL, Blackhurst DW, Latham BB, et al. Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg. 2013;216(4):545-556.
29. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg. 2013;23(4):427-436.
30. Rubino F, Kaplan LM, Schauer PR, Cummings DE; Diabetes Surgery Summit Delegates. The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg. 2010;251(3):399-405.
31. Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013;23(1):93-102.
32. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.
33. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-591. (Pubitemid 351214285)
34. Nathan DM, Cleary PA, Backlund JY, et al Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653. (Pubitemid 41817713)
35. Gerstein HC, Miller ME, Byington RP, et al Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559. (Pubitemid 351831356)
36. Patel A, MacMahon S, Chalmers J, et al ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572. (Pubitemid 351831357)
37. Duckworth W, Abraira C, Moritz T, et al VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
38. Sjöström L, Gummesson A, Sjöström CD, et al Swedish Obese Subjects Study. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10(7):653-662.
39. Flum DR, Dellinger EP. Impact of gastric bypass operation on survival: a population-based analysis. J Am Coll Surg. 2004;199(4):543-551. (Pubitemid 39420204)
40. Christou NV, Sampalis JS, Liberman M, et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg. 2004;240(3):416-423.
41. MacDonald KG Jr, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality of non-insulindependent diabetes mellitus. J Gastrointest Surg. 1997;1(3):213-220. (Pubitemid 127432762) Kidney Diseases Kidney Diseases Diseases